Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term observational study of joint replacement outcomes in prior tanezumab trial participants
2013-002549-12Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tanezumab in osteoarthritis (OA), knee osteoarthritis (OA) and hip osteoarthritis (2 arms), sponsored by Pfizer. Primary endpoint: Surgeon's Assessment of Procedural Difficulty. Started Jul 2015; status: completed.
02
Drugs
tanezumab
03
Conditions
osteoarthritis (OA)knee osteoarthritis (OA)hip osteoarthritis
Beyond the preview
Go deeper on 2013-002549-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002549-12.